Actavis Completes Forest Laboratories Acquisition LEARN MORE>
Actavis Completes Forest Laboratories Acquisition
>Go!

United States

Allergan in the United States

Actavis

Actavis’ U.S. Generics business is the dominant source of revenue for the Company with approximately 84% of total generic net revenue coming from the Company’s business in this market. The Company is focused on maintaining a leading position in the U.S. generics market, where it currently holds approximately 10% market share. In 2011, Actavis expanded its U.S. generic product line with the launch of 18 generic products. In addition to the generic versions of CONCERTA® and LIPITOR®, the Company launched generics of Famvir®, KADIAN®, Keppra XR®, AMRIX®, and new oral contraceptives including AmethiaTM (a generic version of SEASONIQUE®), Amethia®Lo (a generic version of Lo SEASONIQUE®), and AmethystTM (a generic version of Lybrel®). In 2011, the Company held a 36% share of the U.S. market in generic oral contraceptives with more than 30 product formulations. During the year, the Company announced the initiation of a number of patent challenges, including challenges to OxyContin®, Vigamox®, Welchol®, Viagra®, Pataday™, AVODART®, Vyvanse®, JALYN™, EMBEDA®, Daytrana®, Atelvia™, and Exelon®.

Actavis >

  • Morris Corporate Center III
  • 400 Interpace Parkway
  • Parsippany, NJ 07054 USA
  • Tel: +1-862-261-7000
  • Website:

Get direction from

Go!

New Jersey Corporate Office

Warner Chilcott is now Actavis.

New Jersey Corporate Office

  • 100 Enterprise Drive
  • Rockaway
  • NJ 07866
  • Tel: (973) 442-3200

Get direction from

Go!

Puerto Rico

Warner Chilcott is now Actavis.

Fajardo, Puerto Rico Facility

  • P.O. Box 1005
  • Fajardo
  • PR 00738-1005
  • Tel: (787) 863-1850

Get direction from

Go!

Manatí, Puerto Rico Facility

  • P.O. Box 1055
  • Manatí
  • PR 00674-1055
  • Tel: (787) 621-4250

Get direction from

Go!

United States - Allergan

On March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team.

The Actavis + Allergan Brand portfolio features six blockbuster franchises in key therapeutic categories, including Dermatology and Aesthetics; CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular and Infectious Disease. Supporting these blockbuster franchises is the company’s industry-leading specialty and primary care U.S. sales force with extraordinary marketing reach and increased relevance with primary care physicians and specialists.

The Actavis + Allergan Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The combined company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.

Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015 alone, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

Actavis Administrative HQ

  • Morris Corporate Center III
  • 400 Interpace Parkway
  • Parsippany, NJ 07054
  • Tel: Tel: 862-261-7000
  • Contact: Actavis Investor Relations - 862-261-7488
  • Contact: Actavis Media Relations - 862-261-8030

Get direction from

Go!

Please be advised that the information contained within this site is specific to Internet operating rules and regulations.